H.C. Wainwright initiated coverage of Coya Therapeutics with a Buy rating and $18 price target. Coya is an emerging biotech company focused on treating neurological conditions using novel immunomodulatory approaches, the analyst tells investors in a research note. The firm says Coya is developing proprietary products focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue